**Core tip:** To our best knowledge, this is the first case where a liver abscess grew *C. paraputrificum*. Although pyogenic liver abscesses caused by *Clostridium* species are extremely rare, early and accurate diagnosis of clostridial hepatic abscess and timely interventions are paramount, as it carries an extremely high morbidity and mortality. However, depending on the exact causative *Clostridium* species, the clinical course can vary unexpectedly.

INTRODUCTION
============

Pyogenic liver abscesses caused by *Clostridium* species are extremely rare\[[@B1]\], and only 57 cases have been reported in the English medical literature (Table [1](#T1){ref-type="table"}). *C. perfringens* was responsible for more than a half of these reported cases. This species carries an extremely high mortality rate, especially when associated with hemolysis\[[@B2]-[@B4]\]. The previously reported 20 *C. perfringens* cases showed a median age of 65 years at the time of presentation\[[@B5]\]. Advanced age, underlying malignancy, liver cirrhosis, and immunocompromised conditions including dialysis, transplant and diabetes mellitus were identified as risk factors\[[@B2],[@B5]-[@B8]\]. Here we present a very unusual case of a healthy 23-year-old female who underwent interventional radiology (IR) embolization for a hepatic adenoma and presented within 24 h with a gas forming hepatic liver abscess and septicemia. Due to the extremely rapid clinical presentation where the embolized tumor was completely replaced by a gas forming abscess within a day, *C. perfringens* was suspected as the causative organism. Unlike many other fatal *C. perfringens* hepatic abscess cases, our patient did not have any signs of hemolysis nor experienced any end-organ failure. Future speciation work-up revealed *C. paraputrificum*. There have been five case reports of septicemia caused by *C. paraputrificum*\[[@B9]-[@B13]\]. However, this is the first case of a gas forming hepatic abscess.

###### 

Fifty-seven reported clostridial hepatic abscess cases in the English medical literature

  **Case**   **Author**                    **Year**   **Age**   **Sex**   **Species**                     **Underlying disease**     **HML**   **SSE**   **TTD**                               **PLM**   **PMI**
  ---------- ----------------------------- ---------- --------- --------- ------------------------------- -------------------------- --------- --------- ------------------------------------- --------- ---------
  1          Fiese\[[@B35]\]               1950       67        M         *C. perfringens*                Cholecystitis              No        Yes       \-                                    No        Yes
  2          Kivel et al\[[@B36]\]         1958       68        F         *C. perfringens*                DM                         Yes       No        5 d                                   No        No
  3          Kahn et al\[[@B37]\]          1972       44        F         *C. septicum*                   Colon cancer               No        Yes       \-                                    Yes       Yes
  4          D'Orsi et al\[[@B38]\]        1979       52        F         *C. septicum*                   Colon cancer               No        Yes       \-                                    Yes       No
  5          D'Orsi et al\[[@B38]\]        1979       51        F         *C. ramosum*                    Melanoma                   Yes       No        2 d                                   Yes       No
  6          D'Orsi et al\[[@B38]\]        1979       29        M         *C. ramosum*, *C. sporogenes*   Peri-ampullaryCa           No        Yes       \-                                    Yes       Yes
  7          Mera et al\[[@B39]\]          1984       6         F         *C. perfringens*                Fanconi's anemia           Yes       No        14 h                                  No        No
  8          Nachman et al\[[@B40]\]       1989       6         M         *C. bifermentans*               Blunt trauma               No        Yes       \-                                    No        No
  9          Yood et al\[[@B41]\]          1989       64        F         *C. perfringens*                Systemic vasculitis        No        Yes       \-                                    No        No
  10         Batge et al\[[@B42]\]         1992       61        M         *C. perfringens*                Pancreatic cancer, DM      Yes       Yes       \-                                    No        No
  11         Rogstad et al\[[@B43]\]       1993       61        M         *C. perfringens*                None                       Yes       No        3 h                                   No        No
  12         Thel et al\[[@B32]\]          1994       39        F         *C. septicum*                   Breast Ca, Bone M. txp     No        Yes       \-                                    Yes       No
  13         Gutierrez et al\[[@B44]\]     1995       74        M         *C. perfringens*                None                       Yes       No        6 h                                   No        No
  14         Jones et al\[[@B45]\]         1996       66        F         *C. perfringens*                OLT, DM                    Yes       No        10 h                                  No        No
  15         Lee et al\[[@B34]\]           1999       33        F         *C. septicum*                   Uterine cancer             No        Yes       \-                                    Yes       No
  16         Eckel et al\[[@B46]\]         2000       65        F         *C. perfringens*                Cholangiocarcinoma         Yes       Yes       \-                                    Yes       Yes
  17         Urban et al\[[@B47]\]         2000       68        M         *C. septicum*                   Colon cancer               No        Yes       \-                                    Yes       No
  18         Sakurai et al\[[@B48]\]       2001       75        F         *C. difficile*                  Hepatic cyst               No        Yes       \-                                    Yes       No
  19         Kreidl et al\[[@B8]\]         2002       80        M         *C. perfringens*                DM, dialysis               Yes       No        11 h                                  No        No
  20         Sarmiento et al\[[@B49]\]     2002       57        M         *C. septicum*                   Colon cancer               No        Yes       \-                                    Yes       No
  21         Hsieh et al\[[@B50]\]         2003       23        M         *Unusual C. spp*.               Blunt trauma               No        Yes       \-                                    No        No
  22         Quigley et al\[[@B51]\]       2003       73        M         *C. perfringens*                Hepatic cyst               \-        No        0 h                                   Yes       Yes
  23         Elsayed et al\[[@B52]\]       2004       27        M         *C. hathewayi*                  Cholecystitis              No        Yes       \-                                    No        No
  24         Fondran et al\[[@B53]\]       2005       63        M         *C. perfringens*                Pancreatic cancer          No        Yes       \-                                    Yes       Yes
  25         Au et al\[[@B7]\]             2005       65        M         *C. perfringens*                DM, dialysis               Yes       No        3 h                                   No        No
  26         Kurtz et al\[[@B54]\]         2005       50        F         *C. septicum*                   Colon cancer               No        Yes       \-                                    Yes       No
  27         Ohtani et al\[[@B55]\]        2006       78        M         *C. perfringens*                DM                         Yes       No        3 h                                   No        No
  28         Daly et al\[[@B56]\]          2006       80        M         *C. perfringens*                DM                         Yes       No        3 h                                   No        No
  29         Loran et al\[[@B57]\]         2006       69        F         *C. perfringens*                None                       Yes       No        6 h                                   No        No
  30         Chiang et al\[[@B58]\]        2007       46        F         *C. perfringens*                Cholecystitis              No        No        7 d                                   No        No
  31         Abdel-Haq et al\[[@B59]\]     2007       11        M         *C. novyi type B*               Blunt trauma               No        Yes       \-                                    No        No
  32         Umgelter et al\[[@B60]\]      2007       87        F         *C. perfringens*                Colon cancer               No        Yes       \-                                    Yes       No
  33         Tabarelli et al\[[@B61]\]     2009       65        F         *C. perfringens*                Pancr. Ca s/p whipple      No        No        27 d                                  No        Yes
  34         Merino et al\[[@B62]\]        2009       83        F         *C. perfringens*                None                       Yes       No        3 d                                   No        No
  35         Saleh et al\[[@B63]\]         2009       53        M         *C. septicum*                   Colon cancer               No        Yes       \-                                    Yes       No
  36         Meyns et al\[[@B64]\]         2009       64        M         *C. perfringens*                DM                         Yes       No        2 d                                   No        No
  37         Ng et al\[[@B4]\]             2010       61        F         *C. perfringens*                DM                         Yes       Yes       \-                                    No        Yes
  38         Rajendran et al\[[@B65]\]     2010       58        M         *C. perfringens*                None                       Yes       Yes       \-                                    No        No
  39         Bradly et al\[[@B66]\]        2010       52        M         *C. perfringens*                OLT                        Yes       No        6 h                                   No        No
  40         Ogah et al\[[@B67]\]          2012       6         F         *C. clostridioforme*            None                       No        Yes       \-                                    No        No
  41         Qandeel et al\[[@B68]\]       2012       59        M         *C. perfringens*                DM, s/p elective chole     Yes       Yes       \-                                    No        No
  42         Kim et al\[[@B69]\]           2012       80        F         *C. perfringens*                Hilar cholangiocarcinoma   No        No        3 d                                   No        Yes
  43         Huang et al\[[@B70]\]         2012       54        M         *C. baratii*                    Cholecystitis              No        Yes       \-                                    No        No
  44         Sucandy et al\[[@B71]\]       2012       65        M         *C. septicum*                   Colon cancer               No        No        2 d                                   Yes       No
  45         Law et al\[[@B5]\]            2012       50        F         *C. perfringens*                Rectal cancer              Yes       No        7 d                                   Yes       No
  46         Raghavendra et al\[[@B72]\]   2013       63        M         *C. septicum*                   Colon cancer               No        Yes       \-                                    Yes       No
  47         Kitterer et al\[[@B73]\]      2014       71        M         *C. perfringens*                OLT, Gastroenteritis       Yes       No        13 h                                  No        No
  48         Imai et al\[[@B74]\]          2014       76        M         *C. perfringens*                None                       Yes       No        6.5 h                                 No        No
  49         Kurasawa et al\[[@B2]\]       2014       65        M         *C. perfringens*                DM                         Yes       No        6 h                                   No        No
  50         Eltawansy et al\[[@B75]\]     2015       81        F         *C. perfringens*                DM, Gastroenteritis        No        No        N/A[1](#T1FN1){ref-type="table-fn"}   No        Yes
  51         Li et al\[[@B76]\]            2015       71        M         *C. perfringens*                HCC, Hepatitis B           Yes       Yes       \-                                    Yes       No
  52         Rives et al\[[@B77]\]         2015       63        M         *C. perfringens*                Colon cancer               No        Yes       \-                                    Yes       No
  53         Lim et al\[[@B6]\]            2016       58        M         *C. perfringens*                None                       Yes       No        7.5 h                                 No        No
  54         Hashiba et al\[[@B78]\]       2016       82        M         *C. perfringens*                DM                         Yes       No        2 h                                   No        No
  55         Kyang et al\[[@B79]\]         2016       84        M         *C. perfringens*                Gastric adenoCA            No        Yes       \-                                    Yes       Yes
  56         Ulger et al\[[@B80]\]         2016       80        F         *C. difficile*                  DM                         No        No        18 d                                  No        No
  57         García et al\[[@B81]\]        2016       65        M         *C. perfringens*                DM                         Yes       Yes       \-                                    No        Yes

Exact time of TTD was not discussed, but terminal vent weaning was initiated and subsequently expired. HML: Hemolysis; SSE: Survival of septic episode; TTD: Time to death; PLM: Presence of liver mass; PMI: Polymicrobial infection.

CASE REPORT
===========

A 23-year-old healthy female with obesity (body mass index of 37 kg/m^2^) and Polycystic Ovarian Syndrome on oral contraceptive pills was evaluated for intermittent, right upper quadrant abdominal pain. She was found to have a hepatic adenoma measuring 5.2 cm × 3.3 cm × 6.6 cm abutting the liver capsule in segment 7 (Figure [1](#F1){ref-type="fig"}) on imaging. The patient's oral contraceptive pill was discontinued for the more than three months, since the adenoma was diagnosed. A repeat computerized tomography (CT) scan did not show regression of the mass (Figure [2](#F2){ref-type="fig"}). Due to ongoing intractable abdominal right upper quadrant pain and risk of potential rupture, a surgical resection was presented as an option *vs* IR-guided embolization as an alternative option given her body habitus and fatty liver on magnetic resonance imaging study. The patient elected to proceed with IR embolization.

![Magnetic resonance imaging of the segment 7 hepatic adenoma measuring 5.2 cm × 3.3 cm × 6.6 cm.](WJH-10-388-g001){#F1}

![Computed tomography after stopping oral contraceptive pills for 3 mo. No change in size.](WJH-10-388-g002){#F2}

Angiogram showed conventional hepatic artery anatomy, and the adenoma was exclusively fed by a single branch coming off of the posterior right hepatic artery (Figure [3](#F3){ref-type="fig"}). The tumor was completely embolized with 100-300 μm trisacryl gelatin microspheres (Embosphere^®^, Merit Medical Systems, Inc., South Jordan, United States). The patient was discharged home the same day.

![Interventional radiology angiogram of the hepatic adenoma.](WJH-10-388-g003){#F3}

The next day, the patient began to experience a rapid onset of right upper abdominal pain, nausea, vomiting and fever of 101.5 °F. In the emergency room, the patient was tachycardic with a heart rate in the 120 s. She experienced right upper abdominal tenderness on physical exam. Blood tests showed a white blood cell (WBC) count of 16.4 Thou/μL, a lactic acid of 2.4 nmol/L, a serum aspartate transaminase (AST) of 671 U/L, a serum alanine transaminase (ALT) of 310 U/L, and a total bilirubin (T. bili) of 1.4 mg/dL. A CT scan showed the embolized tumor in segment 7 completely replaced with multiple gas pockets (Figure [4](#F4){ref-type="fig"}). A set of blood cultures was sent, and the patient was started on vancomycin, levofloxacin and metronidazole (patient has a penicillin allergy). The next day, the set of blood cultures grew gram positive rods. The patient's serum WBC was elevated to 25 Thou/μL. Later that day, the preliminary blood culture revealed *clostridium* species. With ongoing fever and the newly diagnosed *clostridium* species infection, a repeat CT scan was performed to rule out potential life threatening gas gangrene. The repeat CT scan showed no changes.

![The tumor completely replaced by gas pockets.](WJH-10-388-g004){#F4}

The patient remained persistently febrile, despite antibiotic therapy and subsequent blood cultures showing no growth. The culture speciation showed *Clostridium paraputrificum* and no other organisms were isolated. Despite improving leukocytosis, an IR-guided drain was placed on hospital day 10 due to the persistent fevers. One hundred and twenty cc of dark turbid sterile fluid was aspirated, and the gram stain showed many neutrophils. No bacteria were isolated. Aspirin was started because the patient's platelet count rose above 500 Thou/μL. Over the next a few days since the drain placement, the fluid character became less turbid. However, the color became frankly bilious. The daily drain output persistently remained less than 200 cc, indicating a low output bile leak. Thus an ERCP was not performed. On Hospital day 16, the patient was afebrile for the first time. The patient was discharged home on hospital day 17 since the patient was afebrile for 48 hours. At the time of discharge, the drain output was less than 100 cc per day and the patient was discharged on oral metronidazole only.

The patient presented two weeks after discharge with a follow-up CT, which revealed a significantly reduced gas filled abscess cavity (Figure [5](#F5){ref-type="fig"}). The IR drain was taken out as the daily output remained minimum, less than 5 cc per day. Oral metronidazole was continued for two more weeks post drain removal. Upon completion of the antibiotic course, blood tests showed a WBC of 9.5 Thou/μL, a platelet count of 379 Thou/μL, an AST of 27 U/L, an ALT of 30 U/L, and a T. bili of 0.6 mg/dL.

![Follow-up computed tomography. The gas pocket reduced.](WJH-10-388-g005){#F5}

DISCUSSION
==========

Pyogenic liver abscess (PLA) is an uncommon disease. Various incidences have been reported throughout the world: 1.1 in Denmark\[[@B14]\], 2.3 in Canada\[[@B15]\] and 17.6 per 100000 population in Taiwan\[[@B16]\]. In the United States, the incidence is 3.6 per 100000 population with a reported in-hospital mortality rate of 5.6%\[[@B17]\].

The incidences of gas forming pyogenic liver abscess (GFPLA), also known as emphysematous liver abscess, are even rarer, contributing 6.6% to 32% of PLA\[[@B16],[@B18]-[@B21]\]. It carries a significantly higher mortality rate, 27.7% to 37.1%\[[@B22]-[@B25]\]. For those who presented with GFPLA, their incidence of septic shock was higher (32.5% *vs* 11.7%) and they presented with a shorter duration of symptoms (5.2 d *vs* 7.6 d) when compared to those who presented with non-gas forming pyogenic liver abscess (NGFPLA)\[[@B22]\].

The single strongest risk factor for GFPLA appears to be the presence of diabetes and poorly controlled blood glucose\[[@B15],[@B18],[@B22]\]. According to a case report series done in Taiwan which compared 83 patients with GFPLA against 341 NGFPLA patients, 85.5% of those with GFPLA had diabetes mellitus with an initial glucose level of 383.0 ± 167.7 (mg/dL) *vs* 33.1% with an initial glucose level of 262.6 ± 158.0 (mg/dL)\[[@B22]\]. Similar findings were reported from another single center series from South Korea, where 76% (19 out of 25) were found to have diabetes when comparing 25 patients with GFPLA against 354 NGFPLA patients\[[@B18]\]. The most common causative organism for GFPLA was *Klebsiella pneumoniae* contributing 77% to 88%\[[@B18],[@B22],[@B25]\]. *Escherichia*, *Streptococcus*, *Enterococcus*, *Pseudomonas*, *Morganella*, *Enterobacter*, *Serratia*, *Bacteroides* and *Clostridium* species were responsible for the remaining\[[@B22]\].

An extremely small portion of GFPLA is caused by clostridial species. The two most commonly reported *clostridium* species are *C. perfringens and C. septicum*. We performed a PubMed literature search and identified 57 *clostridium* hepatic abscess cases reported in the English medical literature (Table [1](#T1){ref-type="table"}). Our search showed that *C. perfringens* was responsible for 37 cases (64.9%) and *C. septicum* was responsible for 10 cases (17.5%). Nine cases were caused by *C. difficile, C. ramosum, C. sporogenes, C. baratii, C. bifermentans, C. clostridioforme, C. hathewayi*, and *C. novyi type B*. In one case, the exact speciation was not provided due to the institution's microbiology limitation for identifying rare clostridial species.

*C. perfringens* septicemia has been reported to carry a mortality rate ranging from 70%-100%\[[@B4]\]. Massive intravascular hemolysis is a well-known complication, occurring in 7%-15% of *C. perfringens* bacteremia cases\[[@B26]-[@B28]\]. *C. perfringens*'s alpha-toxin has been shown be the key virulent factor for this clinical course, by inducing gas gangrene and causing massive hemolysis by destroying red cell membrane integrity\[[@B3]\]. In our 37 cases of *C. perfringens* hepatic abscess, the mortality rate was 67.6% (25/37). 70.2% (26/37) experienced hemolysis (Table [1](#T1){ref-type="table"}). Among the 25 patients who died, one patient died prior to arriving to the hospital. The mean time of survival for these 24 patients was 11 h. Among the 25 patients who died, only 4 patients (16%) were found to have poly-microbial infection, whereas among those who survived, 6 patients (50%) were found to have poly-microbial infection. The most common underlying disease was diabetes (11/37) followed by underlying malignancy (10/37). Interestingly, 7 patients were found to have no clear underlying medical disease.

Among the 10 cases of *C. septicum* species (Table [1](#T1){ref-type="table"}), the patient survival was greater, 70% (7/10). Furthermore, no hemolysis was reported in contrast to the *C. perfringens* cases. Of note, *C. septicum also* produces alpha toxin, but it was shown to be unrelated to the alpha toxin of *C. perfringens*\[[@B29]\]. *C. septicum* infection has been well known to be associated with underlying occult malignancy\[[@B30]-[@B33]\]. It has been hypothesized that a rapidly growing tumor with anaerobic glycolysis provides a relatively hypoxic and acidic environment for germination of the clostridial spores\[[@B34]\]. In fact, all of the ten patients had infected liver tumors at the time of the presentation, and only one patient (10%) was found to have a poly-microbial infection.

The remaining 10 cases where the infection was caused by various clostridial species, including the one with no provided speciation, appeared to have a milder clinical course when compared to the above *C. perfringens* and *C. septicum* cohorts (Table [1](#T1){ref-type="table"}). The mortality rate was lower, only 20%, and median age at the time of presentation was significantly younger, 27 years. Interestingly, trauma was the underlying disease for the three cases.

Here, we report a young, healthy 23-year-old female who was diagnosed with a hepatic abscess caused by *Clostridium paraputrificum*. Due to the extremely rapid clinical presentation and from the initial imaging study where the mass was completely replaced with multiple gas pockets, a *C. perfringens* infection was highly suspected. Unlike many typical *C. perfringens* hepatic abscess cases, our patient did not experience hemolysis nor had any end organ failure requiring ICU care. In addition, our patient did not have the typical risk factors for *C. perfringens* nor *C. septicum* infections, except for having a tumor in the liver. At the end, the causative organism was identified as *Clostridium paraputrificum*, which has not been reported before in the literature. A *Clostridium* hepatic abscess is an extremely rare case and *C. perfringens* is the most common causative organism. Early accurate diagnosis and timely interventions are paramount, as it carries an extremely high mortality. However, depending on the exact causative clostridial species, the clinical course can vary significantly.

ARTICLE HIGHLIGHTS
==================

Case characteristics
--------------------

A healthy 23-year-old female developed a *Clostridium paraputrificum* gas forming liver abscess within 24 h after interventional radiology hepatic adenoma embolization.

Clinical diagnosis
------------------

The patient's source of sepsis was unequivocally identified once an imaging study showed a gas forming liver abscess.

Differential diagnosis
----------------------

*Klebsiella pneumonia* was suspected to be the causative organism initially as it is known to contributing 77% to 88% of all gas forming pyogenic liver abscesses.

Laboratory diagnosis
--------------------

In addition to severe leukocytosis and lactic acidosis, elevated lactate dehydrogenase, deceased haptoglobin and elevated bilirubin, signs of massive hemolysis, can be also seen in certain patients.

Imaging diagnosis
-----------------

A gas forming liver abscess can be diagnosed with an abdominal X-ray or ultrasound, but typically a computed tomography scan is commonly used for the diagnosis.

Pathological diagnosis
----------------------

A needle aspiration of the hepatic abscess and/or blood culture often will yield the causative organism.

Treatment
---------

An early recognition and treatment with antibiotics is paramount as *Clostridium* hepatic abscess infections are often extremely aggressive and lethal.

Related reports
---------------

There have been five case reports of septicemia caused by *C. paraputrificum*, however, none of them caused hepatic abscess.

Term explanation
----------------

Pyogenic liver abscess (PLA) is an uncommon disease. The incidences of gas forming pyogenic liver abscess (GFPLA) also known as emphysematous liver abscess, are even rarer, contributing 6.6% to 32% of PLA.

Experiences and lessons
-----------------------

A *Clostridium* hepatic abscess requires early accurate diagnosis and timely interventions, as it carries an extremely high mortality. However, depending on the exact causative clostridial species, the clinical course can vary significantly.
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